1. Introduction
===============

Hepatocellular carcinoma (HCC) is the fifth most commonly occurring malignancy and the second leading cause of cancer mortality worldwide with ∼782,000 new cancer cases in 2012 worldwide.^\[[@R1]\]^ China alone accounts for 51% of HCC related death annually worldwide, with approximately 383,000 people die from liver cancer every year.^\[[@R2]\]^ Besides, the incidence of HCC has doubled during the last 20 years in the United States and Europe.^\[[@R3]\]^ Liver transplantation (LT), hepatectomy, and radiofrequency ablation (RFA) are potentially curative therapies for HCC patients.^\[[@R4]\]^ However, only a minority of patients are amenable. The majority of patients receive nonsurgical therapies, such as transarterial chemoembolization (TACE), concurrent chemoradiation therapy (CCRT) and systemic chemotherapy, as they might have poor performance status, serious medical comorbidities, intermediate or advanced stage tumor, compromised hepatic reserve and so on. Further, even in small HCC, recurrence rate can be almost 70% within 5 years after resection.^\[[@R4]\]^ Therefore, the long-term prognosis of HCC patients is still far from satisfactory and identifying prognostic factors before and during treatment is paramount for subsequent therapy.

Alpha-fetoprotein (AFP) is a glycoprotein expressed by HCC and secreted into the serum in approximately 70% of patients.^\[[@R5]\]^ It has been extensively studied as a screening, diagnosis, surveillance, recurrence monitoring, and prognostic prediction tool for HCC.^\[[@R4],[@R6]--[@R8]\]^ The post-treatment decline of AFP levels was shown to indicate a good treatment response as it possibly reflected decreased tumor burden and activity.^\[[@R9],[@R10]\]^ In contrast, elevation of AFP after therapy might represent re-expansion of the tumor, either by incomplete treatment or de novo tumor.^\[[@R11]\]^ Therefore, post-treatment AFP response may serve as an easy, objective, and non-invasive tool to monitor treatment efficacy. However, results were not consistent.^\[[@R12]\]^ This meta-analysis is aimed at investigating the correlation between post-treatment AFP response and prognosis of HCC by reviewing published studies.

2. Methods
==========

2.1. Study identification
-------------------------

We searched 4 major databases, including PubMed, EMBASE, Web of Science and Cochrane library databases for relevant articles. As there were various definitions and cut-off values in previous studies, we used the following search items: (fetoprotein OR AFP) AND (response OR change or responses or changes or increase or decrease) AND (liver cancer OR liver carcinoma OR hepatoma OR hepatocellular carcinoma OR HCC OR hepatic carcinoma OR hepatic cancer OR hepatocellular cancer). The last search was performed on March 20, 2019. This meta-analysis was conducted in accordance with the guidelines provided by the PRISMA statement. The patient consent and approval from institutional review board were not necessary as the data in our study were extracted from published literatures.

2.2. Study eligibility and selection
------------------------------------

Studies were eligible if HCC cases were stratified by post-treatment AFP response. Furthermore, they should report a risk estimate \[e.g., hazard ratio (HR)\] relating post-treatment AFP response to survival and its 95% confidence interval (CI). Exclusion criteria were as follows:

1.  duplicates,

2.  comments,

3.  errata,

4.  reviews,

5.  case reports,

6.  experimental studies,

7.  if dual (or multiple) studies were reported by the same institution and/or authors, either the higher quality or more recent publication was included in the analysis. Literatures were limited to English-language.

Only published studies in peer-review journals were included.

2.3. Data extraction and quality assessment
-------------------------------------------

Two investigators (CH and XL) independently reviewed all potentially eligible studies and collected data on study characteristics. Discrepancies were resolved by discussion and consensus. We extracted the following data from the included studies: first author, journal, publication year, study region, enrollment period, number of patients, AFP response definition, HR and its 95% CI. We selected estimate of HR from multivariate regression over univariate regression if several estimates were reported in the same article. The Newcastle--Ottawa Scale (NOS) was used to assess study quality.^\[[@R13]\]^

2.4. Data synthesis and analysis
--------------------------------

Statistical analyses were performed by using Review Manager Software (RevMan 5.3; Cochrane Collaboration, Oxford, UK). The prognostic values of post-treatment AFP response to overall survival (OS), progression-free survival (PFS) and recurrence-free survival (RFS) were estimated by using HR with 95% CI. Sensitivity analyses were performed to determine the stability of the pooled results. The Mantel--Haenszel Q-statistic and the I^2^ statistic were used to assess heterogeneity among studies. We considered *P* \>.10 /I^2^ ≤50% to indicate no significant heterogeneity, and in such cases, a fixed-effect model was selected. Conversely, we considered *P* ≤.10 /I^2^ \>50% to indicate significant heterogeneity, and a random effect model was used. All *P* values were 2-tailed, and *P* \<.05 indicated statistical significance in the integration results. Publication biases were evaluated by the Begg funnel plots.

3. Results
==========

3.1. Eligible studies
---------------------

The flow chart of study selection process was shown in Figure [1](#F1){ref-type="fig"}. Briefly, 364 citations were identified initially, 87 duplicates were excluded by endnote X7 software. After reviewing the titles and abstracts, 231 irrelevant citations were excluded. We reviewed the full text of the rest 46 studies, and 18 studies were excluded for no available data. Finally, 29 studies with 4726 HCC patients were included for analyses.^\[[@R7],[@R9]--[@R11],[@R14]--[@R38]\]^ All included studies were retrospective. There were 24 studies from Asia, 3 studies from Europe, and 2 studies from USA. Ten studies defined post-treatment AFP response as \>50%/≥50% reduction from baseline AFP level. Ten studies defined post-treatment AFP response as \>20%/≥20% reduction from baseline AFP level. Three studies defined post-treatment AFP response as any reduction/AFP ratio (post-treatment AFP/baseline AFP) ≤1.0. Two studies defined post-treatment AFP response as AFP ratio ≤1.2. Three studies defined post-treatment AFP response as normalization, AFP slope ≤15 ng/mL/month and lgAFP7 /lgAFP0 ≤0.8135 respectively. The main characteristics of eligible studies were summarized in Table [1](#T1){ref-type="table"}.
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Characteristics of included studies.
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3.2. Post-treatment AFP response and OS
---------------------------------------

Twenty-eight studies provided information regarding OS. Lee MH et al. reported 2 cohorts of HCC patients, which received CCRT and hepatic artery infusion chemotherapy (HAIC) respectively.^\[[@R22]\]^ The 2 cohorts were analyzed independently. The pooled HR of post-treatment AFP response for OS was significant (HR = 0.41, 95% CI: 0.35 - 0.47, *P* \<.001, Fig. [2](#F2){ref-type="fig"}A.), indicating that HCC patients with post-treatment AFP response had better OS than those without AFP response. Random effect model was applied as high statistical heterogeneity existed with I^2^ value of 60% (*P* \<.001). Subgroup analyses according to different therapies, cut-off values of AFP reduction from baseline AFP level and regions of studies were performed. The pooled HRs of post-treatment AFP response for OS in subgroup analyses were all significant (Table [2](#T2){ref-type="table"}A, 2B, 2C).
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Subgroup analyses for the effect of post-treatment AFP response on OS.
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3.3. Post-treatment AFP response and RFS
----------------------------------------

Six studies provided data concerning RFS. As shown in Figure [2](#F2){ref-type="fig"}B, the pooled HR of post-treatment AFP response for RFS was significant (HR = 0.41, 95% CI: 0.29--0.56, *P* \<.001), indicating that HCC patients with post-treatment AFP response had better RFS. Random effect model was also applied as I^2^ value was 71% (*P* \<.001).

3.4. Post-treatment AFP response for PFS
----------------------------------------

Eleven studies provided data concerning PFS. As shown in Figure [2](#F2){ref-type="fig"}C, the pooled HR of post-treatment AFP response for PFS was significant (HR = 0.46, 95% CI: 0.39--0.54, *P* \<.001), indicating that patients with post-treatment AFP response had better PFS. Fixed effect model was applied as I^2^ value was 0% (*P* \<.001).

3.5. Sensitivity analysis and Publication bias
----------------------------------------------

Sensitivity analysis was performed to determine the impact of each individual study on the overall results by removal 1 study each time. The pooled HR of post-treatment AFP response for OS varied from 0.40 (95% CI: 0.34--0.46) to 0.42 (95% CI: 0.37--0.49). The pooled HR of post-treatment AFP response for RFS varied from 0.36 (95% CI: 0.24--0.54) to 0.47 (95% CI: 0.36--0.61). The pooled HR of post-treatment AFP response for PFS varied from 0.44 (95% CI: 0.37--0.53) to 0.47 (95% CI: 0.40--0.56). The results showed that any single study had little influence on the pooled results, thus indicating that our results were relatively stable and credible. Funnel plots suggested no evidence of notable publication bias (Fig. [3](#F3){ref-type="fig"}).
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4. Discussion
=============

Treatment response in HCC patients was heterogeneous. Some patients showed impressive treatment effects, while others showed limited or no response. Thus, methods to predict treatment response would be of great utility. Radiological evaluation is the gold standard for response evaluation of HCC after systemic therapy or other non-surgical modalities, such as mRECIST criteria. However, radiological evaluation has been criticized for several reasons. First, radiological evaluation can be challenging in the background of cirrhosis. Second, it is difficult to measure tumor size when HCC grows in an infiltrative pattern. Third, previous studies showed that mRECIST criteria failed to predict survival at an early time point.^\[[@R39]\]^ Finally, radiological evaluation is relatively subjective and lacks inter-observer reproducibility.^\[[@R40]\]^ The present meta-analysis highlighted AFP response as a noninvasive prognostic marker for HCC, which is an attractive alternative to radiological evaluation. Furthermore, post-treatment AFP response has wider application than radiological evaluation as it can predict the survival of HCC patients who received LT, hepatectomy, and RFA. There were several explanations for post-treatment AFP response to predict HCC prognosis.

First, for HCC patients who received curative therapies, preoperatively elevated AFP levels were indicative of high tumor aggressivity, and AFP was reported to be a predictor of microvascular invasion (MVI).^\[[@R41]\]^ Postoperative non-responders might indicate that either treatment was incomplete or there were either intra or extra-hepatic occult metastasis. There was a dilemma between wide negative margin and adequate functional liver remnants. Moreover, large tumors tend to have satellite and MVI. Therefore, residual cancer cells may be left after hepatectomy and lead to a low rate of AFP normalization. Second, for HCC patients who received locoregional therapy (LRT) or systemic therapy, AFP decrease might be caused by hypoxia and tumor necrosis.^\[[@R28],[@R42]\]^ Conversely, AFP increase was associated with HCC progression.^\[[@R11]\]^ Third, AFP participated in the pathogenesis of HCC. Li, et al reported that AFP promoted proliferation of human hepatoma cells through cAMP-PKA pathway and intracellular calcium to regulate the expression of oncogenes.^\[[@R43],[@R44]\]^ And they also reported that AFP elicited the escape of hepatoma cells from the host\'s lymphocytes immune surveillance by promoting the expression of FasL and TRAIL in hepatoma cells and Fas and TRAILR in lymphocytes.^\[[@R45]\]^ Mizejewski et al reported that cytoplasmic AFP had a lethal role in oncogenesis, growth, and metastasis in liver cancer.^\[[@R46]\]^ Lu Y reported that AFP promoted invasion and metastasis of HCC cell via up-regulating expression of metastasis-related proteins.^\[[@R47]\]^ Mitsuhashi N reported that poor prognosis associated with high AFP was due to high cell proliferation, high angiogenesis, and low apoptosis of HCC.^\[[@R48]\]^ Briefly, AFP promotes the growth, proliferation, and metastasis of HCC, and AFP prevents apoptosis and escaping of HCC from immune surveillance. Therefore, it is plausible for HCC patients with post-treatment AFP response to have better prognosis over those without AFP response.

The present meta-analysis has several limitations. First, all included studies were retrospective and observational, and the patient numbers in several studies were relative small. Second, there might be publication bias as studies with negative results are generally difficult to be published. Third, we only included English-language studies in peer-review journals, which might have introduced selection bias. Fourth, therapies and follow-up lengths among studies were not consistent, which added heterogeneity to our analysis. Last but not the least, there were several definitions of post-treatment AFP response. Further studies are needed to standardize the definitions of post-treatment AFP response for specific treatment modalities.

5. Conclusion
=============

In summary, the present meta-analysis suggests that post-treatment AFP response could predict the survival in HCC patients.
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